Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Abstract

Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.

Keywords

GefitinibMedicineInternal medicineLung cancerEpidermal growth factor receptorOncologyClinical endpointChemotherapyPlaceboCancerRandomized controlled trialPathology

Affiliated Institutions

Related Publications

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Sharon Barr , Stuart Thomson , Elizabeth Buck +10 more

Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin. As carcinomas progress, these tumors may lose epithelial morphology and acquire mes...

2008 Clinical & Experimental Metastasis 199 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

Pui San Tan , Gilberto Lopes , Sanchalika Acharyya +2 more

Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...

2015 European Journal of Cancer 17 citations

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Elizabeth Buck , Alexandra Eyzaguirre , Sharon Barr +7 more

Abstract Overexpression and enhanced activation of the epidermal growth factor receptor (EGFR) is frequently observed in human carcinomas. Inhibitors of EGFR signaling have show...

2007 Molecular Cancer Therapeutics 186 citations

Publication Info

Year: 2003
Type: article
Volume: 290
Issue: 16
Pages: 2149-2149
Citations: 2523
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2523

OpenAlex

Cite This

APA Style

                            
                                
                                    Mark G. Kris, 
                                
                                    Ronald B. Natale, 
                                
                                    Roy S. Herbst
                                
                                et al.
                            
                            (2003). 
                            Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer. 
                            JAMA
                            , 290
                            (16)
                            , 2149-2149.
                            https://doi.org/10.1001/jama.290.16.2149
                        

Identifiers

DOI: 10.1001/jama.290.16.2149